Connect Conference & Show Floor Educational Sessions

View, browse and sort the list of Connect Conference sessions and show floor programming by pass type, track, and format. Please note, all Connect Conference delegates have access to CPhI Connect and InformEx Connect programming. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.

To learn more about the Connect Conference program, click here.

All SessionsSpeakersMy Schedule
View Sessions As:
  
  • Spotlight Luncheon Panel Discussion: 1 CDMO? 4 Perspectives

    Moderator:
    • Rita Peters  |  Editorial Director, Pharmaceutical Technology and BioPharm International
    Panelists:
    • Robert C. Fry, Jr., PhD, CBE  |  Chief Economist, Robert Fry Economics LLC & Former Senior Economist, DuPont
    • Anil Kane  |  Executive Director, Global Head of Formulation Sciences, Patheon
    • Doug Johnson  |  President/Consultant, OCAM Solutions, Inc.
    • Paul Nelson  |  Vice President, Supply Chain and R&D, Amring Pharmaceuticals Inc
    Location:  120ABC
    Track: Drug Development
    Pass Type: Connect Delegate, VIP Attendee, Exhibitor, Connect Delegate - Get your pass now!
    Vault Recording: TBD

    Join us for lunch and an engaging panel discussion about the benefits of taking a 360-degree view of your COMO engagement model. Four experts will offer valuable perspectives on their areas of expertise and why partnering with a single COMO may offer your molecule its best chance at success.

    • The Economics View, from Robert Fry, Jr., Ph.D., CBE, Chief Economist, Robert Fry Economics LLC

    • The Early Development Science View from Anil Kane, Executive Director and Head of Formulation Sciences, Patheon

    • The Consultant View from Doug Johnson, President/CMC-Product Development Consultant at OCAM Solutions, Inc.

    • The Executive View from Paul Nelson Vice President, Supply Chain and R&D at Amring Pharmaceuticals Inc.

    You'll hear about the economics of a more holistic drug development and manufacturing model, challenges and opportunities in develop­ ment, business-centric lessons learned, tips on meeting critical milestones, and how to meet your investor's financial expectations.